2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1679

Different Cut-Offs for Renal Resistive Index Reflect Renal and Other Organ Involvement and Predict Worsening in SSc Patients
Abstract Number: 1680

Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis
Abstract Number: 1681

An Evaluation of Two Novel Techniques Utilising a Smartphone Digital Camera in the Assessment of Nailfold Capillaries in Suspected Scleroderma-Spectrum Disorders: A Single-Center Cross-Sectional Study
Abstract Number: 1682

Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing
Abstract Number: 1683

Smoking Behaviour and the Progression of Organ Manifestations in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study
Abstract Number: 1684

Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 1685

Factors Associated with the 6-Minute Walk Distance in Patients with Systemic Sclerosis
Abstract Number: 1686

Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Abstract Number: 1687

Efficacy of Rituximab for Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Study of 28 Patients
Abstract Number: 1688

Stem Cell-Enriched Lipotransfer Substantially Improves Measures of Appearance and Function Due to Facial Fibrosis in Systemic Sclerosis
Abstract Number: 1689

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Sclerosis
Abstract Number: 1690

Nailfold Capillary Counts Are Associated with Clinical Manifestations in Connective Tissue Disease Japanese Patitents
Abstract Number: 1691

Risk of Development of Definite Disease in Patients with Early Systemic Sclerosis
Abstract Number: 1692

Decreased Lean Body Mass, Body Fat and Bone Mineral Density in Scleroderma Patients Are Associated with Disease Activity and Physical Activity
Abstract Number: 1693

To What Extend Do Auto-Antibodies Help to Identify High-Risk Patients in Systemic Sclerosis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].